- RSS Channel Showcase 4220169
- RSS Channel Showcase 8799819
- RSS Channel Showcase 3960003
- RSS Channel Showcase 9464918
Articles on this Page
- 06/16/17--18:24: _Pembrolizumab With ...
- 06/16/17--18:32: _Combined immunother...
- 06/17/17--18:33: _Trial of Melanoma T...
- 06/17/17--18:37: _Pembrolizumab plus ...
- 06/20/17--04:21: _Glembatumumab Vedot...
- 06/20/17--04:50: _Melanoma-Specific S...
- 06/21/17--19:30: _Dr. Ascierto on Tri...
- 06/17/17--18:33: Trial of Melanoma Triplet Combo Raises Questions
Pembrolizumab (Keytruda) in combination with entinostat, an HDAC inhibitor, showed clinical activity in patients with melanoma who had progressed on or following treatment with checkpoint inhibitors, as well as an acceptable safety profile.
A combination of two immunotherapy drugs is safe to give to patients with melanoma, a type of skin cancer, that has spread to the brain, and could help control the disease.
Source: Targeted Oncology, June 2017 A 3-drug regimen for advanced melanoma led to objective responses in a majority of patients with advanced BRAF-mutant disease but also proved to be somewhat toxic, a small phase II study showed.1 Results showed that 22 of 42 patients (52.4%) had complete or partial responses when treated with the BRAF […]
CHICAGO — The combination of standard-dose pembrolizumab and low-dose ipilimumab led to robust and durable antitumor activity with a manageable safety profile in patients with advanced melanoma, according to mature data from KEYNOTE-029.
Patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor demonstrated promising overall response rate (ORR) and duration of response (DOR) in a phase II study involving the antibody-drug conjugate (ADC) glembatumumab vedotin (GV).
The phase III MSLT-II trial showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel node metastasis, although a benefit was observed in regional disease control.
Source: OncLive, June 2017 Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses findings from a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetinib, and ribociclib (Kisqali) in patients with BRAF V600-mutant solid tumors and melanoma. This is the […]